Ortho-Mcneil Pharmaceutical Corp.

Ortho Pharmaceutical Corporation

Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Ortho-Mcneil Pharmacueticals

Wai-Ping Leung

Per A Peterson

Lars Karlsson

Ellen Chi

Steven D Goldberg

Patricia Andrade-Gordon

Timothy W Lovenberg

Chichi Huang

Xiaohua Xue

Lubing Zhou

Ronald Swanson

Andrew Lawrence Darrow

Wilson Edwards

Alan Wickenden

John J Siekierka

Young Yang

Crafford A Harris

Navin Rao

Christopher Alfonso

Joseph R Voland

Trudy Christiansen-Weber

Tobias Preckel

Aimee Rose De Leon-Tabaldo

Amy Strasner

Jonathan Blevitt

The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.

Kv1.3 antagonists and methods of use

IRAK 1c [Interleukin-1 Receptor-Associated Kinase 1c] splice variants and their preparation and use are described. The splice variants may be used in drug screening assays and methods for diagnosing medical conditions mediated by IRAK 1c-modulating activity.

IRAK 1c splice variant and its use

A transgenic animal with alterations in the histamine H3 receptor gene is prepared by introduction of an altered histamine H3 receptor gene into a host animal. The resulting transgenic animals do not produce functional histamine H3 receptor molecules. Cells and cell lines derived from these animals also contain the altered histamine H3 receptor gene.

Histamine receptor H3 modified transgenic mice

A transgenic animal with alterations in an H2-O gene is prepared by introduction of an altered H2-O gene into a host animal. The resulting transgenic animals produce a substantially greater frequency of high affinity antibodies compared to H2-O wild type animals. A method for the production of high affinity antibodies is disclosed.

Methods for Producing B cells and antibodies from H2-O modified transgenic mice

A transgenic mouse with alterations in an abc1 gene is prepared by introduction of an altered abc1 gene into a host animal. The resulting transgenic mice do not produce functional ABC1 protein molecules. Cells and cell lines derived from these animals also contain the altered abc1 gene.

ATP-binding cassette transporter (ABC1) modified transgenic mice

A transgenic mouse with alterations in a PA28&bgr; gene is prepared by introduction of an altered PA28&bgr; gene into a host mouse. The resulting transgenic animals do not produce functional PA28 molecules. Cells and cell lines derived from these animals also contain the altered PA28&bgr; gene.

PA28 modified transgenic mice

A transgenic animal with alterations in an IRAK gene is prepared by introduction of an altered IRAK gene into a host animal. The resulting transgenic animals do not produce functional IRAK molecules. Cells and cell lines derived from these animals also contain the altered IRAK gene.

IRAK modified transgenic animals

Transgenic mice with a non-functional proteinase activated receptor-2 (PAR2) gene are prepared by targeted disruption of the endogenous PAR2 gene. The resulting transgenic mice display a phenotype including a lack of a hypotensive response to administration of the peptide, SLIGRL, and a reduction in carrageenin-induced paw edema compared to wild type mice.

PAR2 modified transgenic mice

A transgenic mouse with alterations in the H2-Ma gene is prepared by introduction of an altered H2-Ma gene into a host mouse. The resulting transgenic mice do not produce functional H2-M molecules.

H2-M modified transgenic mice

A transgenic animal with alterations in an thrombin receptor gene is prepared by introduction of an altered thrombin receptor gene into a host animal. The resulting transgenic animals do not produce functional thrombin receptor molecules.

Thrombin receptor deficient transgenic mice

Growing community of inventors

San Diego, CA, United States of America

Wai-Ping Leung